Merck & Co.’s Keytruda Achieves $7 Billion in Quarterly Sales, Surpassing Expectations

Sales Milestone: Merck & Co.'s Keytruda has reached $7.3 billion in quarterly sales, a 16% increase from the previous quarter.
Analyst Forecasts: The sales figure exceeded analyst forecasts of $7.1 billion.
Winrevair Debut: The debut of Winrevair has also outperformed expectations.
Market Impact: This performance has contributed to Merck & Co. beating both EPS and revenue expectations for the second quarter.
Product Significance: Keytruda is a leading oncology drug, demonstrating strong market performance and contributing significantly to Merck & Co.'s financial success.